Rare but dangerous blood clotting associated with that vaccine as well as AstraZeneca’s had a genetic cause, according to a new paper.

Researchers identify genetic mutation in small group of people who developed the serious disorder after receiving the AstraZeneca or Johnson & Johnson vaccine.

When reports of rare but severe blood clots emerged after Johnson & Johnson’s COVID vaccine, they threatened to overshadow an otherwise successful immunization campaign and left scientists searching ...

Research led by Christian Medical College in Vellore, India, has demonstrated the successful use of lentiviral vectors to deliver gene therapy for patients with severe hemophilia A. The study presents ...

Hemophilia A and B are similar conditions that affect the blood’s ability to clot. They typically occur due to gene variations that affect different blood clotting factors. Hemophilia is a group of ...

There has been a small incidence of diffuse clotting, especially in atypical body sites, like the central vein draining the brain, among some AstraZeneca and J&J COVID-19 vaccine recipients. A newly ...